All In Biotech

Drug Trial Radar · NCT07758920

A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Sponsor type
Industry
First posted
Aug 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial to evaluate the safety, efficacy and pharmacokinetic (PK) profile of HL-1186 Tablet in patients with postherpetic neuralgia (PHN).

Conditions

  • Postherpetic Neuralgia ( PHN )

Interventions

  • HL-1186Drug

    HL-1186 tablet for oral administration

  • HL-1186 placeboDrug

    HL-1186 placebo tablet for oral administration

  • Pregabalin capsuleDrug

    Pregabalin capsule for oral administration

  • Pregabalin capsule placeboDrug

    Pregabalin capsule placebo for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Average Daily Pain Score (ADPS) from baseline after 12 weeks of administrationTime frame: Day 1 to Day 84

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.